The aim of the present study was to investigate the possible relation between the efficacy of PD-1 blockade therapy and pretreatment plasma levels of sPD-1 and sPD-L1 across a broad range of advanced cancers that had limited clinical focus. This evidence concerns the gene PDCD1 and cancer.